S Atallah1,2, H Al-Assaf1,2, Y Xu1, S El-Sayed1,2. 1. Radiation Medicine Program, The Ottawa Hospital, and. 2. Division of Radiation Oncology, University of Ottawa, Ottawa, ON.
Abstract
PURPOSE: We reviewed the experience of a tertiary cancer centre in the management of adrenocortical carcinoma (acc) treated over 40 years. We also searched the literature for guidelines related to the treatment of acc and for evidence for adjuvant radiation therapy (rt). METHODS: In a retrospective chart review, acc patients treated between January 1974 and December 2013 were identified, and patient demographics and tumour characteristics were extracted. Outcomes data, including dates and sites of failure, vital status, and cause of death, were collected. Overall survival was estimated using the Kaplan- Meier method. A medline search using PubMed, Ovid, and embase was used to review the literature about the role of rt and any available management guidelines for acc. RESULTS: Of 81 patients identified during the chart review, 39 had confirmed acc. In 32 patients, surgical resection was performed, including in 2 patients with M1 disease. Of those 32 patients, 16 received adjuvant systemic treatment (mitotane or concurrent chemoradiation). Only 6 patients received adjuvant rt, of whom 3 are still alive (2 living with distant failure). At a median follow-up of 3.8 years, 28 patients had died (72%), 10 were living (26%), and 1 had been lost to follow-up. Of the 22 patients for whom failure data were available, 2 experienced local failure, and the rest, distant failure. CONCLUSIONS: The current data are insufficient to make treatment recommendations. Use of collaborative databases and consensus about diagnostic and therapeutic guidelines are warranted for better identification of optimum management. Adjuvant rt could be a reasonable option for R1 disease, but further research is needed.
PURPOSE: We reviewed the experience of a tertiary cancer centre in the management of adrenocortical carcinoma (acc) treated over 40 years. We also searched the literature for guidelines related to the treatment of acc and for evidence for adjuvant radiation therapy (rt). METHODS: In a retrospective chart review, acc patients treated between January 1974 and December 2013 were identified, and patient demographics and tumour characteristics were extracted. Outcomes data, including dates and sites of failure, vital status, and cause of death, were collected. Overall survival was estimated using the Kaplan- Meier method. A medline search using PubMed, Ovid, and embase was used to review the literature about the role of rt and any available management guidelines for acc. RESULTS: Of 81 patients identified during the chart review, 39 had confirmed acc. In 32 patients, surgical resection was performed, including in 2 patients with M1 disease. Of those 32 patients, 16 received adjuvant systemic treatment (mitotane or concurrent chemoradiation). Only 6 patients received adjuvant rt, of whom 3 are still alive (2 living with distant failure). At a median follow-up of 3.8 years, 28 patients had died (72%), 10 were living (26%), and 1 had been lost to follow-up. Of the 22 patients for whom failure data were available, 2 experienced local failure, and the rest, distant failure. CONCLUSIONS: The current data are insufficient to make treatment recommendations. Use of collaborative databases and consensus about diagnostic and therapeutic guidelines are warranted for better identification of optimum management. Adjuvant rt could be a reasonable option for R1 disease, but further research is needed.
Authors: Ricardo J Gonzalez; Suzanne Shapiro; Nicholas Sarlis; Rena Vassilopoulou-Sellin; Nancy D Perrier; Douglas B Evans; Jeffrey E Lee Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: Aaron Sabolch; Mary Feng; Kent Griffith; Gary Hammer; Gerard Doherty; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-01 Impact factor: 7.038
Authors: A Berruti; E Baudin; H Gelderblom; H R Haak; F Porpiglia; M Fassnacht; G Pentheroudakis Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: Aaron Sabolch; Tobias Else; Kent A Griffith; Edgar Ben-Josef; Andrew Williams; Barbra S Miller; Francis Worden; Gary D Hammer; Shruti Jolly Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-05 Impact factor: 7.038
Authors: P Sèbe; J Rigaud; C Avancès; L Brunaud; C Caillard; P Camparo; B Carnaille; X Durand; A Fléchon; T Murez; M Mathonnet; F Triponez; E Mirallié; P Coloby; M Soulié Journal: Prog Urol Date: 2013-11 Impact factor: 0.915
Authors: J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau Journal: N Engl J Med Date: 1990-04-26 Impact factor: 91.245
Authors: Laila A Gharzai; Michael D Green; Kent A Griffith; Tobias Else; Charles S Mayo; Elizabeth Hesseltine; Daniel E Spratt; Edgar Ben-Josef; Aaron Sabolch; Barbara S Miller; Francis Worden; Thomas J Giordano; Gary D Hammer; Shruti Jolly Journal: J Clin Endocrinol Metab Date: 2019-09-01 Impact factor: 6.134
Authors: Mark J McCabe; Mark Pinese; Chia-Ling Chan; Nisa Sheriff; Tanya J Thompson; John Grady; Marie Wong; Marie-Emilie A Gauthier; Clare Puttick; Velimir Gayevskiy; Elektra Hajdu; Stephen Q Wong; Wade Barrett; Peter Earls; Robyn Lukeis; Yuen Y Cheng; Ruby C Y Lin; David M Thomas; D Neil Watkins; Marcel E Dinger; Ann I McCormack; Mark J Cowley Journal: Cold Spring Harb Mol Case Stud Date: 2019-04-01